[go: up one dir, main page]

AR059927A1 - Metodos para la estabilizacion de composiciones inestables a la oxidacion y composiciones oftalmicas estabilizadas - Google Patents

Metodos para la estabilizacion de composiciones inestables a la oxidacion y composiciones oftalmicas estabilizadas

Info

Publication number
AR059927A1
AR059927A1 ARP070101089A ARP070101089A AR059927A1 AR 059927 A1 AR059927 A1 AR 059927A1 AR P070101089 A ARP070101089 A AR P070101089A AR P070101089 A ARP070101089 A AR P070101089A AR 059927 A1 AR059927 A1 AR 059927A1
Authority
AR
Argentina
Prior art keywords
compositions
oxidation
methods
ophthalm
stabilization
Prior art date
Application number
ARP070101089A
Other languages
English (en)
Original Assignee
Johnson & Johnson Vision Care
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson & Johnson Vision Care filed Critical Johnson & Johnson Vision Care
Publication of AR059927A1 publication Critical patent/AR059927A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Composiciones oftálmicas y métodos para la preparacion de dichas composiciones. Reivindicacion 1: Un método para estabilizar una composicion oftálmica que comprende un ingrediente farmacéutico inestable a la oxidacion, donde dicho método comprende la adicion de una cantidad efectiva de un agente estabilizador a la composicion oftálmica. Reivindicacion 2: El método de acuerdo con la reivindicacion 1, en el cual el agente estabilizador es seleccionado del grupo constituido por sílice, derivados de quitina tales como quitosana, celulosa, sus derivados y N,N,N',N',Nö,Nö-hexa(2-piridil)-1,3,5-tris(aminometil)benceno, ácido dietilentriaminopentaacético y las sales del ácido dietilentriaminopentaacético.
ARP070101089A 2006-03-17 2007-03-16 Metodos para la estabilizacion de composiciones inestables a la oxidacion y composiciones oftalmicas estabilizadas AR059927A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US78355706P 2006-03-17 2006-03-17

Publications (1)

Publication Number Publication Date
AR059927A1 true AR059927A1 (es) 2008-05-07

Family

ID=38421691

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070101089A AR059927A1 (es) 2006-03-17 2007-03-16 Metodos para la estabilizacion de composiciones inestables a la oxidacion y composiciones oftalmicas estabilizadas

Country Status (13)

Country Link
US (4) US8466174B2 (es)
EP (1) EP2010143B1 (es)
JP (1) JP5275214B2 (es)
KR (3) KR20140083056A (es)
CN (1) CN101420934B (es)
AR (1) AR059927A1 (es)
AU (1) AU2007227091B2 (es)
BR (1) BRPI0709549A2 (es)
CA (2) CA2908828C (es)
HK (2) HK1127998A1 (es)
RU (2) RU2462234C2 (es)
TW (1) TWI454286B (es)
WO (1) WO2007109523A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3150209T3 (pl) * 2006-03-31 2020-03-31 Vistakon Pharmaceuticals, Llc Leczenie alergii oczu
EP3210594B1 (en) 2006-09-29 2023-09-13 Johnson & Johnson Vision Care, Inc. Methods and ophthalmic devices used in the treatment of ocular allergies
US20090239954A1 (en) * 2008-03-19 2009-09-24 Collins Gary L Phosphate buffered ophthalmic solutions displaying improved efficacy
US20100226999A1 (en) * 2009-03-06 2010-09-09 Tracy Quevillon-Coleman Process for forming stabilized ophthalmic solutions
IT1393419B1 (it) * 2009-03-19 2012-04-20 Medivis S R L Composizioni oftalmiche a base di acidi grassi polinsaturi omega-3 e omega-6.
JP5675183B2 (ja) * 2009-06-16 2015-02-25 ロート製薬株式会社 水性組成物
US20120225918A1 (en) 2011-03-03 2012-09-06 Voom, Llc Compositions and Methods for Non-Surgical Treatment of Ptosis
EP3369422A4 (en) * 2015-10-29 2018-12-05 Teika Pharmaceutical Co., Ltd. External preparation
CN119235862A (zh) 2018-03-09 2025-01-03 博尔托拉制药公司 选择性syk抑制剂的使用方法及药物组合物
US10814001B1 (en) 2019-05-06 2020-10-27 Rvl Pharmaceuticals, Inc. Oxymetazoline compositions
AU2021318237A1 (en) * 2020-07-30 2023-03-09 Rohto Pharmaceutical Co., Ltd. Aqueous composition

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4304762A (en) * 1978-09-27 1981-12-08 Lever Brothers Company Stabilization of hydrogen peroxide
DD150694A1 (de) * 1980-04-16 1981-09-16 Gisela Raether Verfahren zur stabilisierung von pharmazeutischen praeparaten mit oxidationsempfindlichen bestandteilen
DE3640708C2 (de) * 1986-11-28 1995-05-18 Schering Ag Verbesserte metallhaltige Pharmazeutika
DE68929516T2 (de) * 1988-08-04 2005-01-05 Novartis Ag Verfahren zur Konservierung ophthalmischer Lösungen und Zusammensetzungen dafür
US5514732A (en) * 1993-07-22 1996-05-07 Johnson & Johnson Vision Products, Inc. Anti-bacterial, insoluble, metal-chelating polymers
AU1716995A (en) 1994-03-18 1995-10-09 Ciba-Geigy Ag Aqueous solution of levocabastine for ophthalmic use
JPH07324034A (ja) 1994-05-30 1995-12-12 Toa Yakuhin Kk フマル酸ケトチフェン含有の点眼剤
US5683993A (en) * 1995-06-22 1997-11-04 Ciba Vision Corporation Compositions and methods for stabilizing polymers
US6020373A (en) * 1995-10-20 2000-02-01 Eastern Virginia Medical School Chelate derivatives as protectors against tissue injury
RU2140236C1 (ru) * 1996-08-20 1999-10-27 Хабаровский филиал МНТК "Микрохирургия глаза" Способ лечения диабетической ретинопатии
AR002194A1 (es) * 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.
US5980882A (en) * 1997-04-16 1999-11-09 Medeva Pharmaceuticals Manufacturing Drug-resin complexes stabilized by chelating agents
JPH11189528A (ja) * 1997-12-26 1999-07-13 Lead Chemical Co Ltd 安定性の改善された皮膚適用製剤
EP0938896A1 (en) * 1998-01-15 1999-09-01 Novartis AG Autoclavable pharmaceutical compositions containing a chelating agent
JPH11279205A (ja) * 1998-03-26 1999-10-12 Nippon Tenganyaku Kenkyusho:Kk ヒアルロン酸類製剤の分解抑制方法
CN1138542C (zh) 1998-04-02 2004-02-18 诺瓦提斯公司 通过特定应用的抗氧化剂稳定药物组合物的方法
CN1114401C (zh) 1998-07-14 2003-07-16 阿尔康实验室公司 11－(3－二甲氨基亚丙基)－6,11－二氢二苯并[b,e]噁庚英－2－乙酸用于制药的新用途
US6395756B2 (en) 1999-12-23 2002-05-28 Novartis Ag Use of ophthalmic agent
RU2196594C2 (ru) * 2000-09-25 2003-01-20 Общество с ограниченной ответственностью "Камелия НПП" Средство, обладающее восстановительным, тонизирующим и регенераторным действием
US20020127281A1 (en) 2000-09-28 2002-09-12 Fu-Pao Tsao Stabilized hyrogen peroxide solutions
TW586946B (en) 2000-12-22 2004-05-11 Novartis Ag Process to improve stability
RU2191012C1 (ru) * 2001-06-20 2002-10-20 Научно-исследовательский испытательный центр (медико-биологической защиты) Государственного научно-исследовательского испытательного института военной медицины МО РФ Глазные капли для лечения эндотелиально-эпителиальной дистрофии роговицы
RU2201213C1 (ru) * 2001-07-04 2003-03-27 Общество с ограниченной ответственностью "Научно-экспериментальное производство Микрохирургия глаза" Глазные капли "карнозин"
AU2002360939A1 (en) * 2001-11-21 2003-06-10 Novartis Ag Composition for stabilizing hyaluronic acid
TWI357331B (en) * 2002-01-18 2012-02-01 Novartis Ag Methods for preserving ophthalmic solutions and pr
WO2004058289A1 (en) * 2002-12-20 2004-07-15 Chakshu Research, Inc. Ophthalmic formulation for the prevention and treatment of ocular conditions
US20050244509A1 (en) * 2004-03-17 2005-11-03 Fu-Pao Tsao Ophthalmic solutions
US20070077303A1 (en) 2005-09-30 2007-04-05 Azaam Alli Methods for providing oxidatively stable ophthalmic compositions
EP3210594B1 (en) * 2006-09-29 2023-09-13 Johnson & Johnson Vision Care, Inc. Methods and ophthalmic devices used in the treatment of ocular allergies

Also Published As

Publication number Publication date
HK1127998A1 (zh) 2009-10-16
RU2012125612A (ru) 2013-12-27
US20170007592A1 (en) 2017-01-12
HK1132176A1 (en) 2010-02-19
US20140011843A1 (en) 2014-01-09
RU2462234C2 (ru) 2012-09-27
CN101420934B (zh) 2014-03-19
KR20150017002A (ko) 2015-02-13
BRPI0709549A2 (pt) 2011-07-19
KR20140083056A (ko) 2014-07-03
AU2007227091A1 (en) 2007-09-27
JP5275214B2 (ja) 2013-08-28
TW200808355A (en) 2008-02-16
AU2007227091B2 (en) 2013-02-07
TWI454286B (zh) 2014-10-01
KR20080111065A (ko) 2008-12-22
WO2007109523A3 (en) 2008-04-10
CN101420934A (zh) 2009-04-29
KR101454674B1 (ko) 2014-10-27
EP2010143A2 (en) 2009-01-07
CA2908828A1 (en) 2007-09-27
JP2009530314A (ja) 2009-08-27
RU2008141172A (ru) 2010-04-27
US9474746B2 (en) 2016-10-25
US20070265234A1 (en) 2007-11-15
CA2646424C (en) 2015-12-29
US8466174B2 (en) 2013-06-18
WO2007109523A2 (en) 2007-09-27
EP2010143B1 (en) 2015-08-12
CA2908828C (en) 2018-01-16
CA2646424A1 (en) 2007-09-27
US20180050026A1 (en) 2018-02-22

Similar Documents

Publication Publication Date Title
AR059927A1 (es) Metodos para la estabilizacion de composiciones inestables a la oxidacion y composiciones oftalmicas estabilizadas
MA45222A (fr) Nouveaux dérivés de pipéridinyle, procédé de préparation de ceux-ci et compositions pharmaceutiques les contenant
MA35750B1 (fr) Dérivés de nucléoside substitué 2',4'-difluoro-2'-méthyle en tant qu'inhibiteurs de la réplication de l'arn du vhc (virus de l'hépatite c)
MA42231B1 (fr) Nouveaux dérivés d'hydroxyacide, leur procédé de préparation, et compositions pharmaceutiques les contenant
BR112012006686B8 (pt) compostos de amida substituída, composições farmacêuticas contendo os ditos compostos, e uso dos mesmos para prevenir e/ou tratar doenças causadas pelo lpa
CR20210201A (es) Nuevos compuestos antihelmínticos
TN2017000467A1 (en) Amido-substituted cyclohexane derivatives
BR112015032623A2 (pt) composto, composição farmacêutica, métodos para tratar doenças e condições, e para degradar o receptor de estrogênio, usos de um composto e de uma combinação, e, combinação
CO2019005729A2 (es) Preparación de complejos sólidos de ciclodextrina para suministro de ingredientes farmacéuticos activos oftálmicos
BRPI0809164B8 (pt) Composição para administração tópica e composição farmacêutica compreendendo a referida composição
NO20082124L (no) Bifenyloksyeddiksyrederivater for behandling av respiratorisk sykdom
BR112015000578A2 (pt) moduladores da via do complemento e usos dos mesmos
BR112015014753A2 (pt) composições, utilização de uma composição, método para o combate dos fungos fitopatogênicos e semente
PE20142294A1 (es) Compuestos de indol e indazol que activan la ampk
BRPI0718176B8 (pt) formulação semissólida de liberação prolongada e controlada, processo para a preparação da composição farmacêutica semissólida
NZ748771A (en) Pharmaceutical compositions comprising nitroxyl donors
BR112013026257A2 (pt) derivados de glicosídeo e usos dos mesmos para o tratamento de diabetes
BR112018011376A2 (pt) composição farmacêutica que compreende um inibi-dor de urat1 potente
NO20083905L (no) Nye pyron-indol derivater og fremgangsmate for deres fremstilling
BR112015010271A8 (pt) produto de comicronização, processo para o preparo de um produto de comicronização, composição farmacêutica e seus usos
MA31094B1 (fr) Utilisation de dérivés de pyranone-acide substituée pour le traitement du syndrome métabolique
EP2722042A4 (en) INDANO DERIVATIVES, PHARMACEUTICALLY ALLOWED SALTS OR OPTICAL ISOMERS THEREOF, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREFORE AS AN ACTIVE AGENT FOR THE PREVENTION OR TREATMENT OF VIRUS DISEASES
BR112013026361A2 (pt) derivados de glicosídeo e usos dos mesmos
BR112021018335A2 (pt) Derivados de benzodiazepina como inibidores de rsv
CO2019004004A2 (es) Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico

Legal Events

Date Code Title Description
FC Refusal